News

Mortality remained elevated even after 20 years poststroke, highlighting the importance of long-term follow-up in this patient population.

The research director and staff scientist at Cleveland Clinic’s Epilepsy Center provided background on the momentum behind MR fingerprinting and its potential in epilepsy care. [WATCH TIME: 3 minutes]

Daridorexant, which will be marketed as Quviviq, will be available later this year after being scheduled by the US Drug Enforcement Administration.

The founder and CEO of Joi Wellness Group Multiple Sclerosis Center explained her reasoning as to why she hopes telemedicine is here to stay. [WATCH TIME: 4 minutes]

Here's what is coming soon to NeurologyLive®.

The association of feelings of worse performance depended on age, with a higher frequency of amyloid positivity at older ages and a lower frequency at lower ages.

Douglas Scharre, MD, discussed the key findings from a recent study evaluating the Self-Administered Gerocognitive Exam and its application for at-risk populations.

Discussing the willingness to share data during the pandemic, the founder and CEO of Joi Life Wellness Group Multiple Sclerosis Center spoke to the positive effect of collaboration in the MS field. [WATCH TIME: 2 minutes]

This now-validated tool showed an ability to accurately identify focal seizure-onset zone, which may help epilepsy centers when faced with the challenge of whether a patient should undergo implantation.

Douglas Scharre, MD, provided an overview of the pen-and-paper and digital versions of the test, which do not require an administrator.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 7, 2022.

The founder and CEO of Joi Life Wellness Group Multiple Sclerosis Center commented on the effect of the pandemic on needs for underrepresented populations in the multiple sclerosis space, as well as the pros and cons of telehealth. [WATCH TIME: 3 minutes]

Patients treated with valbenazine demonstrated favorable outcomes on all secondary outcomes over placebo, as well showed no new safety signals.

The director of the Alzheimer's Disease Care, Research and Education Program at the University of Rochester offered an extensive overview of 3 monoclonal antibodies in development for Alzheimer disease. [WATCH TIME: 9 minutes]

The Jazz Pharmaceuticals’ product, which was FDA approved in August 2021, demonstrated clinically meaningful differences compared with placebo on several secondary end points, including impression of change scales and various and questionnaires.

The authors noted that future studies should investigate this association to identify patients with obstructive sleep apnea who are at risk of potential cognitive decline and adverse health function.

Investigators assert there is still room for improvement to further minimize exposure, as the treatment was used in a relevant number of pregnancies in 2016.

Discussing adaptations to the comprehensive care model in multiple sclerosis, the founder of MS Bites commented on the need to consistently incorporate dietitians. [WATCH TIME: 6 minutes]

Six months post-surgery, patients on either general anesthesia or local anesthesia demonstrated similar motor improvements, indicated by scores on the MDS-UPDRS, as well as similar safety findings.

The clinical psychologist at Cleveland Clinic discussed the process for successfully changing and tailoring different cognitive behavioral therapy approaches to treat various forms of seizures. [WATCH TIME: 3 minutes]

Anne-Maree Kelly, MD, director, Joseph Epstein Center for Emergency Medicine Research, detailed the complexities of presenting migraine in the emergency department and why consensus international/national guidelines tailorable to the capabilities of institutions is necessary.

Investigators also pointed to the potential repetitive administration of the SAGE test to identify stability or decline, effectively providing an objective cognitive biomarker.

Invesitgators from the SoSTART trial recommend further research into whether oral anticoagulation use is superior to aversion to it for preventing symptomatic major vascular events.

The founder of MS Bites discussed the role of referrals both to and from dietitians, as well as the common misconception that their services are not covered by insurance. [WATCH TIME: 2 minutes]

DMT discontinuation resulted with new disability worsening and/or progression in previously stable patients with relapsing-remitting MS and particularly in patients with previously stable secondary progressive MS.

The director of the Chambers-Grundy Center for Transformative Neuroscience at the University of Nevada–Las Vegas detailed the steps necessary to lower wasted costs from Alzheimer disease drug development and improve regulatory success. [WATCH TIME: 4 minutes]

The research assistant professor at the Buffalo Neuroimaging Analysis Center discussed the importance of continued research on how patients with multiple sclerosis experience cognitive decline as they age.

Data indicate that noncontrast CT may be an alternative to CTP or MRI for patients with proximal anterior circulation occlusion stroke who are candidates for mechanical thrombectomy.